What to Know About This Natera Insider Transaction as Shares Surge to Record Highs
Moshkevich's non-discretionary sale was executed to cover tax withholding on vesting RSUs under a Rule 10b5-1 plan.
Overview
Solomon Moshkevich, president of clinical diagnostics at Natera, Inc. (NASDAQ:NTRA), sold 3,410 shares of common stock on August 3, according to an SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($265.58); post-transaction value based on the August 3 market close ($270.36).
Details
Natera is a leading molecular diagnostics company with a market capitalization of $39.4 billion and TTM revenue of $2.7 billion, positioning it among the largest players in the genetic testing sector. The company has achieved substantial scale with a diversified test portfolio addressing multiple clinical indications across reproductive health and hereditary disease screening. Despite current net losses, Natera's strong revenue growth trajectory and commanding market position reflect investor confidence in the expanding demand for non-invasive genetic testing solutions.
Source
Originally published at www.fool.com.